Familial Adenomatous Polyposis Clinical Trials 2023

What are the top hospitals conducting familial adenomatous polyposis research?

In the realm of clinical trials for familial adenomatous polyposis (FAP), several top hospitals are making significant strides in research and treatment. The University of Michigan Comprehensive Cancer Center, located in Ann Arbor, is actively conducting two FAP trials while having a history of three such studies. Their dedication to advancing knowledge about this rare genetic condition was first demonstrated in 2017 when they recorded their inaugural FAP trial. Similarly, the Washington University School of Medicine in Saint Louis is committed to finding innovative solutions for FAP with two ongoing clinical trials and a total of three past trials. They embarked on their journey to tackle FAP in 2018.

A notable contributor to FAP research is the Cleveland Clinic Foundation situated in Cleveland, Ohio. With two active clinical trials and a track record of three completed ones, this institution has been at the forefront of combating FAP since its first trial recording back in 2017. Moving westward to Salt Lake City, Utah, we find Huntsman Cancer Institute and the University of Utah collaborating on efforts related to familial adenomatous polyposis. Despite being relatively new entrants into this field with only two active trials and an equal number of completed ones thus far; these institutions have already made waves by launching their very first trial targeting FAP as recently as 2021.

Lastly but certainly not least important is Boston's Dana-Farber Cancer Institute which also joined forces against familial adenomatous polyposis through their dual active clinical investigations accompanied by prior successful participation encompassing another pair; theirs began more recently than any other establishment mentioned here-just last year,in2022.These dedicated hospitals serve as beacons for patients affected by FAP across the country - offering hope through cutting-edge research aimed at better understanding and ultimately treating this complex hereditary disorder

Which are the best cities for familial adenomatous polyposis clinical trials?

When it comes to familial adenomatous polyposis clinical trials, several cities offer opportunities for research and advancements in care. Ann Arbor, Michigan and Cleveland, Ohio both have 4 active trials studying a range of treatments like Obeticholic Acid, Prevention methods (ONC201, biopsy, sigmoidoscopy, colonoscopy), and Encapsulated Rapamycin (eRapa). Boston, Massachusetts follows closely with 3 ongoing trials focusing on Obeticholic Acid and Cohort 2d. Houston, Texas also has 3 active trials exploring Familial Adenomatous Polyposis (FAP) along with Obeticholic Acid. Lastly, San Antonio Texas participates with 2 active trials investigating Cohort 2d and Encapsulated Rapamycin (eRapa). These cities provide individuals affected by familial adenomatous polyposis access to cutting-edge clinical research that can potentially improve their prognosis and quality of life.

Which are the top treatments for familial adenomatous polyposis being explored in clinical trials?

Obeticholic Acid stands out as the leading treatment currently being explored in clinical trials for familial adenomatous polyposis. With two ongoing trials and a total of two all-time dedicated to this condition, Obeticholic Acid shows promise for patients with this disorder. Its first listing in 2022 highlights its relatively recent entry into the field, signaling potential advancements in managing familial adenomatous polyposis. Further research and evaluation will shed more light on Obeticholic Acid's effectiveness in treating this inherited colorectal cancer syndrome.

What are the most recent clinical trials for familial adenomatous polyposis?

Exciting advancements are occurring in the realm of familial adenomatous polyposis (FAP), with recent clinical trials offering new hope for patients. Notably, REC-4881 4mg has entered Phase 2 and shows promising potential as a treatment option for FAP. Another trial, Cohort 2d, is progressing through both Phase 1 and Phase 2 stages, investigating an innovative approach to tackling FAP. Additionally, a preventive study involving ONC201 combined with biopsy, sigmoidoscopy, and colonoscopy offers insight into early detection methods for FAP. Lastly, Obeticholic Acid has shown promise in two separate phases of clinical trials—Phase 2 conducted on January 29th,2023,and Phase 1 initiated on March31st ,2022.These ongoing studies bring us closer to enhancing outcomes and improving the quality of life for individuals affected by FAP.

What familial adenomatous polyposis clinical trials were recently completed?

Recent advancements in clinical trials for familial adenomatous polyposis (FAP) have shown promising results in the pursuit of improved treatments. In November 2021, Janssen Research & Development completed a trial investigating the potential of JNJ-64251330 to target this hereditary condition characterized by multiple polyps in the colon and rectum. Another significant milestone occurred in November 2018 when Janssen Research & Development concluded a trial examining Guselkumab for FAP treatment. These trials signify important steps forward in understanding and combating FAP, offering hope to individuals affected by this genetic disorder.